Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 5/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23043281 | 0.84 | HTR1A (0.32) | HTR1ASLC6A4 | |
| SCHEMBL29680450 | 0.84 | HTR1A (0.32) | HTR1ASLC6A4 | |
| SCHEMBL30711797 | 0.79 | CA12 (0.32) | — | |
| SCHEMBL31243107 | 0.78 | HTR1A (0.31) | HTR1ASLC6A4 | |
| SCHEMBL25533309 | 0.77 | KMT2A (0.35) | ALDH1A1 | |
| SCHEMBL29207265 | 0.74 | ROR1 (0.34) | SLC6A4ALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29679938 | 0.73 | HSD17B10 (0.39) | — | |
| SCHEMBL28906398 | 0.73 | CYP3A4 (0.39) | ALDH1A1 | |
| SCHEMBL23043132 | 0.73 | HSD17B10 (0.39) | — | |
| SCHEMBL31243002 | 0.73 | CYP3A4 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | MAOA 4869/4885MAOB 4848/4885HTR1A 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.